Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 12/20 | 0.54 |
| ▸ | APOB | P04114 | 7/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794905 | 0.94 | MTTP (0.52) | MTTPAPOBGAAPOLBSMN1; SMN2 | |
| SCHEMBL13351330 | 0.89 | KDM4E (0.59) | MTTPAPOBGAAPOLBSMN1; SMN2 | |
| SCHEMBL6793895 | 0.88 | FFAR1 (0.57) | MTTPAPOBSMN1; SMN2PTGS1FFAR1 | |
| SCHEMBL6788109 | 0.87 | MTTP (0.56) | MTTPAPOBGAASMN1; SMN2PTGS1 | |
| SCHEMBL6793291 | 0.84 | PTGS1 (0.56) | MTTPAPOBGAASMN1; SMN2PTGS1 | |
| SCHEMBL6789828 | 0.84 | PTGS1 (0.58) | MTTPAPOBGAASMN1; SMN2PTGS1 | |
| SCHEMBL6787993 | 0.84 | MTTP (0.54) | MTTPAPOBSMN1; SMN2PTGS1FFAR1 | |
| SCHEMBL7035904 | 0.83 | MTTP (0.49) | MTTPAPOBGAASMO | |
| SCHEMBL6915464 | 0.83 | GAA (0.56) | MTTPAPOBGAAPOLBSMN1; SMN2 | |
| SCHEMBL6791890 | 0.82 | MTTP (0.59) | MTTPAPOBGAASMN1; SMN2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885APOB 1/4885GAA 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.